Drug Profile
NTx 265
Alternative Names: Beta-hCG + EPO; NTx-265; NTx-265 regimen; β-hCG + EPOLatest Information Update: 29 Nov 2021
Price :
$50
*
At a glance
- Originator Stem Cell Therapeutics Corp.
- Developer Trillium Therapeutics Inc
- Class Neuroprotectants; Peptide hormones; Pituitary gonadotropins; Placental hormones; Recombinant erythropoietins; Recombinant proteins
- Mechanism of Action Cell differentiation stimulants; Chorionic gonadotropin stimulants; Erythropoiesis stimulants; Neuron stimulants; Ovarian follicle stimulants; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Stroke